Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

224P - Predictive value of FDG PET/CT parameters and T-cell subsets in stage II/III non-small cell lung cancer with neoadjuvant immunotherapy

Date

28 Mar 2025

Session

Poster Display session

Presenters

EUN SEONG LEE

Citation

Journal of Thoracic Oncology (2025) 20 (3): S123-S150. 10.1016/S1556-0864(25)00632-X

Authors

E.S. LEE1, S. Lee1, S. Kim2, J. Choi1, J.H. Lee1, J.S. Eo1, H.K. Kim1, H.S. Yong1, S.M. Park3, C.J. Chen3, H. Robinson3, P.R. Dunbar3, S.Y. Lee1

Author affiliations

  • 1 Korea University Guro Hospital, Seoul/KR
  • 2 Korea University Guro Hospital, 152-703 - Seoul/KR
  • 3 The University of Auckland, Auckland/NZ

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 224P

Background

This study aims to assess the utility of FDG PET/CTderived parameters as predictive imaging biomarkers in the neoadjuvant setting and their association with specific T cell subsets.

Methods

Patients with clinical stage II/III NSCLC who underwent immunotherapy-based neoadjuvant therapy and had both pre- and post-treatment FDG PET/CT scans were retrospectively included. Biopsy specimens obtained prior to treatment were analyzed to quantify T cell subsets. The maximum standardized uptake value (maxSUV) and tumor to liver ratio (TLR) were measured in total tumors of each patient. Immune cell populations were quantified digitally as percentages.

Results

Eleven pairs of PET images and 8 corresponding biopsy specimens were analyzed. Among the cases, the ratio of patients achieving pathological complete response (pCR) versus no-pCR was 6:5 and 4:4, respectively. Pre-treatment maxSUV and TLR were not significantly different between pCR vs. no-pCR groups. However, post-treatment maxSUV and TLR tended to be lower or were significantly lower in the pCR group (median, 2.570 vs. 4.720, p=0.052 and 1.505 vs. 2.140, p < 0.01, respectively). Additionally, changes in maxSUV (△maxSUV) and TLR (△TLR) were significantly higher in the pCR group (0.83 vs. 0.49, p < 0.01, and 0.82 vs. 0.58, p < 0.01, respectively). Granzyme B (+) CD8 cells of CD8 cells were significantly elevated in the pCR group compared to no-pCR (49.575 vs. 21.11, p < 0.05) and TIGIT (+) CD8 cells of CD8 cells also showed a trend toward higher levels (25.26 vs. 5.805, p=0.057). Pre-treatment TLR showed a positive correlation with Ki67(+) CD8 cells of total cells (r=0.714, p < 0.05). △TLR showed a positive correlation with TIGIT (+) CD8 cells of CD8 cells (r=0.786, p < 0.05) and TIGIT (+) CD8, CD3, CD4 cells of total cells (all, r=0.714, p < 0.05).

Conclusions

The TLR and maxSUV parameters from FDG PET/CT hold potential as non-invasive imaging biomarkers for predicting responses to neoadjuvant immunotherapy in NSCLC. These parameters are significantly associated with markers of T cell activation and exhaustion, underscoring their relevance in understanding the tumor immune microenvironment.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.